

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* EMPFIELD JAMES R.			2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ EVP, Drug Discovery		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/04/2022			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
200 - 3650 GILMORE WAY			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	A1	V5G 4W8						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	03/04/2022		M		25,000	A	\$8.4	35,000	D	
Common Shares	03/04/2022		F		6,685	D	\$31.42 ⁽¹⁾	28,315	D	
Common Shares	03/04/2022		S		18,315	D	\$30.79 ⁽²⁾	10,000	D	
Common Shares	03/07/2022		M		2,500	A	\$8.4	12,500	D	
Common Shares	03/07/2022		F		695	D	\$30.23 ⁽³⁾	11,805	D	
Common Shares	03/07/2022		M		40,000	A	\$6.76	51,805	D	
Common Shares	03/07/2022		F		8,952	D	\$30.23 ⁽³⁾	42,853	D	
Common Shares	03/07/2022		S		1,805	D	\$30.62	41,048	D	
Common Shares	03/07/2022		S		31,048	D	\$30.54 ⁽⁴⁾	10,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$8.4	03/04/2022		M			25,000	(5)	03/12/2027	Common Shares	25,000	\$0.00	0	D	
Stock Option (Right to Buy)	\$8.4	03/07/2022		M			2,500	(5)	03/12/2027	Common Shares	2,500	\$0.00	0	D	
Stock Option (Right to Buy)	\$6.76	03/07/2022		M			40,000	(6)	02/07/2026	Common Shares	40,000	\$0.00	0	D	

Explanation of Responses:

- Represents the closing price of the Company's common shares on March 3, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from \$30.21 to \$31.0296, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from \$30.5161 to \$30.6208, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
- Vesting 25% on February 9, 2017 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Remarks:

/s/ Cassandra Robinson,
Attorney-in-fact

03/08/2022

** Signature of Reporting Person

Date

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.